BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.080
-0.020 (-1.82%)
Apr 24, 2026, 10:46 AM EDT - Market open
BioXcel Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover BioXcel Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $23, which forecasts a 2,029.63% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $66.
Price Target: $23 (+2,029.63%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +362.96% | Apr 2, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +1,474.07% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +455.56% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +825.93% | Sep 15, 2025 |
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +270.37% | Sep 12, 2025 |
Financial Forecast
Revenue This Year
1.91M
from 642.00K
Increased by 197.82%
Revenue Next Year
19.31M
from 1.91M
Increased by 910.15%
EPS This Year
-3.25
from -5.73
EPS Next Year
-1.98
from -3.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 3.5M | 32.2M | ||||||
| Avg | 1.9M | 19.3M | ||||||
| Low | 754,600 | 5.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 439.7% | 1,585.9% | ||||||
| Avg | 197.8% | 910.1% | ||||||
| Low | 17.5% | 173.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.46 | -1.18 | ||||||
| Avg | -3.25 | -1.98 | ||||||
| Low | -6.58 | -2.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.